Our global partnerships allow us to draw on both individual and collective expertise in scientific discoveries and drug development. We are proud to have participated in the following collaborations:
Recent findings suggest that high brain iron levels may be associated with Alzheimer's disease. Together with the National Health and Medicine Research Council of Australia, ApoPharma is supporting an investigation to determine if deferiprone, a drug that lowers brain iron levels, would slow the progression of Alzheimer's disease in its early stages.
For more information, please visit: National Collaborative Research Infrastructure Strategy of Australia
Two ApoPharma-sponsored studies in patients with a rare disorder involving brain iron overload were recently concluded. Neurodegeneration with Brain Iron Accumulation (NBIA) is a group of rare inherited movement disorders that usually begin in childhood, are relentlessly progressive, and cause severe disability, eventually leading to premature death. The most common NBIA disorder is pantothenate kinase-associated neurodegeneration (PKAN). TIRCON (Treat Iron-Related Childhood-Onset Neurodegeneration) is a research consortium comprising 13 partners from 8 countries and funded by the EU. Along with members of this consortium, the two ApoPharma sponsored studies were looking at the effect of deferiprone in patients with PKAN. These studies were conducted from 2011 to 2017, and reports are now being prepared for publication. Through a compassionate-use program, ApoPharma is continuing to provide deferiprone at no cost to patients who completed the studies.
For more information, please visit: www.tircon.eu